Castle Biosciences (CSTL) Gains from Investment Securities (2018 - 2022)

Castle Biosciences has reported Gains from Investment Securities for 3 years, with the latest figure at -$300000.0 in Q4 2022.

• Quarterly Gains from Investment Securities changed N/A year-over-year to -$300000.0 in Q4 2022, while the trailing twelve-month figure through Sep 2023 was -$300000.0 (up 98.33% YoY) and the FY2022 annual result came in at -$18.3 million, changed N/A from the prior year.
• Gains from Investment Securities retreated to -$300000.0 in Q4 2022 per CSTL's latest filing, from -$151000.0 in the prior quarter.
• Over five years, Gains from Investment Securities peaked at $2.6 million in Q1 2022 and troughed at -$20.4 million in Q2 2022.
• A 3-year average of -$1.9 million and a median of $42797.0 in 2018 frame the typical range for Gains from Investment Securities.
• The widest YoY moves for Gains from Investment Securities: up 1145.41% in 2019, down 1145.41% in 2019.
• Over 3 years, Gains from Investment Securities stood at $242544.0 in 2018, then soared by 119.75% to $533000.0 in 2019, then sank by 156.29% to -$300000.0 in 2022.
• According to Business Quant data, Gains from Investment Securities over the past three periods registered -$300000.0, -$151000.0, and -$20.4 million for Q4 2022, Q3 2022, and Q2 2022 respectively.